Alaunos Therapeutics Inc   (TCRT)
Other Ticker:  
Price: $4.2200 $-0.06 -1.402%
Day's High: $4.3571 Week Perf: -37.76 %
Day's Low: $ 4.04 30 Day Perf: -49.16 %
Volume (M): 50 52 Wk High: $ 26.00
Volume (M$): $ 210 52 Wk Avg: $7.12
Open: $4.24 52 Wk Low: $0.44

 Market Capitalization (Millions $) 1,013
 Shares Outstanding (Millions) 240
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) -40
 Capital Exp. (TTM) (Millions $) 0

Alaunos Therapeutics Inc
We are a clinical-stage oncology-focused cell therapy company developing adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We are leveraging our cancer hotspot mutation TCR library and our proprietary, non-viral Sleeping Beauty gene transfer platform to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including KRAS, TP53 and EGFR. In collaboration with The University of Texas MD Anderson Cancer Center, or MD Anderson, we are currently enrolling patients for a Phase 1/2 clinical trial evaluating 12 TCRs reactive to mutated KRAS, TP53 and EGFR from our TCR library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers, which we refer to as our TCR-T Library Phase 1/2 Trial.

We believe that to be successful in treating solid tumors, genetically modified T cells targeting one or more neoantigens will likely need to address the fact that (1) among a population of patients, not all tumors express the targeted neoantigen, referred to as inter-tumor heterogeneity, and (2) within a single patient, not all tumor cells express the targeted antigen, referred to as intra-tumor heterogeneity. Inter-tumor heterogeneity limits the number of recipients that are eligible to receive a treatment and intra-tumor heterogeneity creates the risk of antigen-escape variants, increasing the likelihood of cancer relapse. As a result, we believe companies developing T cell therapies targeting neoantigens must address both inter- and intra-tumor heterogeneity.
We genetically modify peripheral blood-derived T cells to express TCRs with specificity to tumor-derived antigens, especially neoantigens, and propagate them to sufficient numbers prior to administration. We aim to overcome the key challenges of targeting neoantigens by using DNA plasmids to reprogram T cells to express introduced TCRs on a patient-by-patient basis. This is designed to help address tumor heterogeneity.

Our TCR-T cells contain multiple different subsets of T cells, including effector and memory T cells. The effector T cells are associated with immediate anti-tumor activity. Memory T cells have greater growth potential relative to the effector T cells. Some of our TCR-T cells are T memory stem cells, which have been described to have the largest capacity for growth and renewal relative to other T-cell populations.

   Company Address: 8030 El Rio Street Houston 77054 TX
   Company Phone Number: 355-4099   Stock Exchange / Ticker: NASDAQ TCRT


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Alaunos Therapeutics Inc

Major Pharmaceutical Preparations Companies Witness Steady Revenue Despite Challenging Third Quarter of 20232. TCRT Records Similar Losses and Revenue Standstill in Third Quarter of 2023 3. Alaunos Therapeutics Inc Exhibits Slight Financial Improvement in Challenging Third Quarter of 20234. Alaunos Therapeutics Inc's Net Deficit Shows Slight Decrease in Fiscal Period Ending September 20235. TCRT and Alaunos Therapeutics Inc Experience Financial Challenges in the Third Quarter of 2023

In the fiscal period ending September 30, 2023, TCRT, a company in the pharmaceutical industry, experienced a loss of $0.04 per share. This represents a similar loss compared to the previous fiscal period as well as the same financial period a year prior. On the other hand, the company's revenue remained unchanged at $0.00 million, which is a significant decline from the $2.91 million reported in the same financial reporting period a year prior.
In comparison, Alaunos Therapeutics Inc, another company in the pharmaceutical sector, reported a net deficit of $8.476 million for the fiscal period ending September 30, 2023. This marks a slight improvement from the deficit of $8.851 million reported in the same financial reporting period a year ago. The company is expected to release its next financial results on March 06, 2024.

Alaunos Therapeutics Inc

Alaunos Therapeutics Inc Reveals Revenue of $0.004 Million in Q2 2023 Financial Report, Demonstrating Steady Operation and Incremental Growth

Alaunos Therapeutics Inc recently disclosed its financial results for the April to June 30, 2023 reporting period. The company reported a revenue of $0.004 million during this period, along with a net loss of $-8.773 million. These figures indicate a significant improvement compared to the corresponding reporting season a year ago when Alaunos Therapeutics Inc had a net loss of $-9.932 million. The company is slated to release its next financial results on November 13, 2023. Additionally, over the past 5 trading days, Alaunos Therapeutics Inc stock has shown a slight increase of 0.19%. However, the stock's year-to-date performance stands at -34.26%, reaching its 52-week low.
Financial Results:
Alaunos Therapeutics Inc reported revenue of $0.004 million in the April to June 30, 2023 reporting period. This figure represents a small increase from the same period last year. While the revenue generated is relatively low, it does indicate that the company is continuing its operations and generating some income.

Alaunos Therapeutics Inc

Alaunos Therapeutics Inc faces concerning contraction in Q1 2023 results

The Major Pharmaceutical Preparations sector researchers are currently examining the numbers from the first quarter of 2023, particularly in terms of operating shortfalls. One company, TCRT, reported an operating shortfall of $-9.672 million for the January to March 31 2023 reporting period. This shortfall is concerning, especially since TCRT did not mention any revenue. However, to put this into context, the company's business achievement during the first quarter of 2022 resulted in a similar operating shortfall of $-9.085 million.
Another company that the researchers are following is an emerging growth corporation that has not announced its revenue thus far. However, to figure out how well it is performing, the analysts compared its current conduct to its business achievement during the first quarter of 2022. The company recorded a shortfall of $-10.048 million for the corresponding period a previous year, which is higher than its shortfall in the first quarter of 2023.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com